News | Patient Engagement | September 15, 2015

Michigan ‘See You in 7’ Program Helps Reduce Heart Failure Readmissions

ACC program encourages early follow-up after hospital discharge

Michigan, See You in 7, heart failure, readmissions, ACC

September 15, 2015 — Michigan hospitals participating in the American College of Cardiology’s “See You in 7” program demonstrated important reductions in 30-day readmission rates for Medicare heart failure patients compared to non-participating hospitals. The improvements came despite only modest increases in seven-day follow-up appointments, according to a study in JACC: Heart Failure.

“See You in 7” is part of the ACC’s Hospital-to-Home initiative, a national quality improvement program aimed at reducing heart disease-related hospital readmissions and improving the transition from hospital to home. “See You in 7” challenges hospitals to ensure all discharged heart failure and heart attack patients have a follow-up appointment scheduled within seven days of hospital discharge.

“Readmissions of heart failure patients remain one of the most important clinical challenges today,” said JACC: Heart Failure Editor-in-Chief Christopher O’Connor, M.D., FACC. “Transitional care programs may represent our best opportunity to reduce the burden on patients and health systems.”

Researchers looked at the seven-day follow-up and 30-day readmission rates for Medicare heart failure patients at 10 hospitals in the Southeast Michigan “See You in 7” Collaborative and compared them to non-participating hospitals both before joining the “See You in 7” program and after one year of participation.

The one-year program included three phases: implementation, intervention and evaluation periods. During implementation, hospitals selected at least one metric from the “See You in 7” toolkit to focus their efforts and measure progress.

Metrics included:

  • Identify heart failure patients prior to discharge;
  • Schedule and document a follow-up visit with a cardiology or primary care doctor within seven days of discharge;
  • Provide patients with documentation of scheduled follow-up;
  • Identify and address barriers to keeping appointment;
  • Ensure patients arrive at scheduled follow-up appointment; and
  • Make discharge summary available to follow-up healthcare providers.

At the end of the program, both participating and non-participating hospitals’ seven-day follow-up rates increased but remained low—31 to 34 percent for participating hospitals and 30 to 32 percent for non-participating hospitals. However, adjusted 30-day readmission rates decreased substantially in participating hospitals compared to non-participating hospitals. Participating hospitals saw readmissions decrease 2.6 percent, while non-participating hospitals saw a 0.6 percent reduction.

“Our study clearly shows there are challenges in coordinating early follow-up care, since increases in seven-day post-discharge follow-up were modest. However, despite this, hospitals in the program stepped up to address deficiencies in post-hospital care and reduce 30-day readmissions,” said Sandra Marie Oliver-McNeil, DNP, ACNP-BC, a study author and assistant professor of nursing at Wayne State University. “Through collaboratively addressing the ‘See You in 7’ goals, hospitals participating in this program learned from each other when helping their patients transition from hospital to home, and they should serve as an encouraging example for other regional hospitals to share best practices.”

According to the study, participating hospitals designated a staff member to document successful seven-day follow-up visits or investigate why the visits did not take place, leading to more engaged patients and caregivers and giving both sides a better understanding of barriers to care. These efforts may have led to the reduced 30-day readmission rates.

Medicare payments per patient also decreased in participating hospitals. Combined payments for inpatient and 30 days of post-discharge care decreased by $182 in participating hospitals and $63 in non-participating hospitals.  

For more information: www.acc.org

Related Content

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization with new data presented at AHA 2018. #AHA18 #AHA2018
News | Heart Failure | November 07, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) s
Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement
News | Heart Failure | November 02, 2018
In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the...
Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

News | Heart Failure | November 01, 2018
November 1, 2018 — Daxor Corp.
NHLBI Pauses CONCERT-HF Heart Failure Trial
News | Heart Failure | October 29, 2018
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is pausing the...
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.

Feature | Heart Failure | October 19, 2018
October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S
Ohio State First in U.S. to Test Shunt Device for Heart Failure
News | Heart Failure | October 04, 2018
The Ohio State University Wexner Medical Center is first in the country to test a new medical device designed to help...
Mitral Regurgitation Volume Reduced at One Year in REDUCE FMR Trial
News | Heart Failure | September 28, 2018
Heart failure patients who received the Carillon Mitral Contour System in the REDUCE FMR clinical trial showed a...
Cardiac Dimensions Randomizes First Patient in CARILLON Trial of Mitral Contour System
News | Heart Failure | September 20, 2018
Cardiac Dimensions announced the company has randomized its first patient in the CARILLON Pivotal Trial.
Overlay Init